Teva’s Global Innovation Strategy: Advancing Healthcare Through Collaboration and Research
Advancing Access to Healthcare through Innovation and Partnerships
Expanding access to medicines and healthcare relies on the continuous creation of evidence-driven solutions to address unmet medical needs. To support this mission, we actively engage in collaborative scientific efforts with academic institutions, research organizations, start-ups, pharmaceutical companies, hospitals, and health maintenance groups.
These partnerships help us discover external innovations that complement our internal R&D objectives. This collaborative approach enhances our scientific presence and accelerates the expansion of our innovative drug pipeline, aligning with the Step-up Innovation focus of our Pivot to Growth strategy. Ultimately, these initiatives aim to reduce the time needed for drug discovery and development and improve the likelihood of identifying successful therapeutic candidates.
Our Model for Innovation and Collaboration
Our innovation strategy is multi-faceted—bridging internal priorities (uncovered through team workshops and consultations) with external opportunities identified via detailed mapping, database analysis, AI-based scouting, and traditional methods. By being actively involved in key trade and industry associations, we strengthen our position within the global biotech ecosystem. As a trusted collaborator, we offer access to industry insights and the expertise of our skilled teams.
Partnerships Across the U.S. and Europe
In the United States, we have strategic innovation partnerships with top academic institutions including Harvard University, Thomas Jefferson University, University of Pittsburgh, University of Oklahoma, and University of Pennsylvania.
In Europe, we’ve been an active participant in the Innovative Medicines Initiative (IMI)—Europe’s largest public-private partnership in life sciences—since 2019. This initiative supports the development of advanced vaccines, medicines, and treatment methods. As of 2024, we are involved in over eight IMI consortia, covering the full spectrum of drug development. Two of the latest projects focus on biologics and biomarker research:
Expanding access to medicines and healthcare relies on the continuous creation of evidence-driven solutions to address unmet medical needs. To support this mission, we actively engage in collaborative scientific efforts with academic institutions, research organizations, start-ups, pharmaceutical companies, hospitals, and health maintenance groups.
These partnerships help us discover external innovations that complement our internal R&D objectives. This collaborative approach enhances our scientific presence and accelerates the expansion of our innovative drug pipeline, aligning with the Step-up Innovation focus of our Pivot to Growth strategy. Ultimately, these initiatives aim to reduce the time needed for drug discovery and development and improve the likelihood of identifying successful therapeutic candidates.
Our Model for Innovation and Collaboration
Our innovation strategy is multi-faceted—bridging internal priorities (uncovered through team workshops and consultations) with external opportunities identified via detailed mapping, database analysis, AI-based scouting, and traditional methods. By being actively involved in key trade and industry associations, we strengthen our position within the global biotech ecosystem. As a trusted collaborator, we offer access to industry insights and the expertise of our skilled teams.
Partnerships Across the U.S. and Europe
In the United States, we have strategic innovation partnerships with top academic institutions including Harvard University, Thomas Jefferson University, University of Pittsburgh, University of Oklahoma, and University of Pennsylvania.
In Europe, we’ve been an active participant in the Innovative Medicines Initiative (IMI)—Europe’s largest public-private partnership in life sciences—since 2019. This initiative supports the development of advanced vaccines, medicines, and treatment methods. As of 2024, we are involved in over eight IMI consortia, covering the full spectrum of drug development. Two of the latest projects focus on biologics and biomarker research:
- RealHOPE: Designed to improve guidelines for handling biologic medications by patients, caregivers, and pharmacies.
- European Platform for Neurodegenerative Diseases (EPND): Aims to create a comprehensive infrastructure for collecting and analyzing clinical and biological data to support biomarker discovery in neurodegenerative diseases.
Israel as a Strategic Innovation Hub
Given our strong historical roots in Israel, the country plays a vital role in our global innovation efforts. Since re-establishing our focus there in 2020, we have initiated around 50 research collaborations with Israeli scientists. These projects have secured 18 grants from the Israel Innovation Authority, with two receiving additional funding in 2024.
Key Israel-based innovation initiatives include:
Given our strong historical roots in Israel, the country plays a vital role in our global innovation efforts. Since re-establishing our focus there in 2020, we have initiated around 50 research collaborations with Israeli scientists. These projects have secured 18 grants from the Israel Innovation Authority, with two receiving additional funding in 2024.
Key Israel-based innovation initiatives include:
- AION Labs: A collaborative venture between Teva, three other pharmaceutical giants, Amazon, and the Israel Biotech Fund, AION Labs fosters AI-driven start-ups in drug development. We support AION with mentorship and active involvement. In 2024, AION launched CombinAble, a start-up for antibody optimization, and we backed Celleryx, which applies AI for early detection of cancer and autoimmune conditions.
- Organospheres: This multi-partner consortium, including start-ups, pharma firms, and academic researchers, is developing a human-based 3D ex-vivo system to potentially replace animal use in preclinical research.
- BioInnovators Forum: We mentor and train 30 PhD and postdoctoral students annually in translational medicine through workshops and an innovation challenge aimed at addressing unmet clinical needs. Over 150 students have taken part since 2020. Notable 2024 projects included a breath-based tuberculosis detection kit and an IVF device enhancing embryo fertilization and implantation. This program also helps us identify top-tier scientific talent for our R&D efforts.
Since 2020:
- 50 collaborations with Israeli scientists
- 18 grants awarded from the Israel Innovation Authority
- 150 BioInnovators Forum participants
Research into Public Health Needs
Our research team gathers and interprets public health and epidemiological data to assess the clinical, economic, and social needs of patients in key therapeutic areas such as neurology, psychiatry, immunology, and oncology. We focus on understanding disease burden, testing innovative clinical education tools, and improving access to treatment. This data also supports trial design by helping to identify the most appropriate patient populations and inclusion criteria. In 2024, we presented findings at 176 scientific conferences and published 55 articles in peer-reviewed medical and scientific journals.
Teva’s 2024 Academic Publications on PubMed (55 total):
Our research team gathers and interprets public health and epidemiological data to assess the clinical, economic, and social needs of patients in key therapeutic areas such as neurology, psychiatry, immunology, and oncology. We focus on understanding disease burden, testing innovative clinical education tools, and improving access to treatment. This data also supports trial design by helping to identify the most appropriate patient populations and inclusion criteria. In 2024, we presented findings at 176 scientific conferences and published 55 articles in peer-reviewed medical and scientific journals.
Teva’s 2024 Academic Publications on PubMed (55 total):
- 33%: Research Innovation
- 29%: Neurology/Psychiatry
- 11%: Migraine
- 7%: Respiratory
- 7%: Oncology
- 5%: Immunology
- 4%: Cardiovascular
- 4%: Central Nervous System/Pain
Companies